Ratings Farmacosmo S.p.A.

Equities

COSMO

IT0005487670

Market Closed - Borsa Italiana Other stock markets 09:14:59 10/05/2024 pm IST			5-day change	1st Jan Change
0.85 ^EUR	+6.52%		+2.41%	+23.91%

30/04	ITALY GROWTH WINNERS & LOSERS: Plants at the top; AATech bearish	AN
12/04	Farmacosmo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.47 for the 2024 fiscal year.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Department Stores

	1st Jan change	Capi.	ESG Refinitiv
FARMACOSMO S.P.A.	+23.91%	35.53M	-
AMAZON.COM, INC.	+23.39%	1,951B	C
JD.COM, INC.	+11.46%	49.27B	B
COUPANG, INC.	+38.97%	40.23B	-
ALLEGRO.EU S.A.	+14.03%	10.04B	B
WAYFAIR INC.	+14.62%	8.62B	C
ETSY, INC.	-23.60%	7.24B	C
ZOZO, INC.	+5.89%	6.4B	B-
FSN E-COMMERCE VENTURES LIMITED	-2.33%	5.81B	D+
MONOTARO CO., LTD.	+17.25%	5.75B	C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes